[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:programmed-cell-death-1-ligand-1":3},{"name":4,"total":5,"recruiting":6,"trials":7},"Programmed Cell Death 1 Ligand 1",125,110,[8,16,22,29,35,41,47,53,59,65,72,78,85,91,97,103,108,114,120,126,132,138,144,150,156,162,168,175,181,187,193,199,205,211,217,223,229,235,241,247,253,259,265,271,276,281,288,294,300,306],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06890598","Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer",[12],"Phase 3","RECRUITING","2026-08-26T02:19:13.549512Z","2026-07-19T19:36:05.058056Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT06692738","A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)",[12],"2026-08-26T02:19:06.150683Z","2026-07-19T19:36:05.037066Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT04150640","Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma",[26],"Phase 2","2026-08-26T02:16:01.910993Z","2026-07-05T05:32:16.773838Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06312137","A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)",[12],"2026-08-26T02:19:02.550788Z","2026-07-05T05:32:16.749560Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06050252","Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery",[26],"2026-08-26T02:16:33.772093Z","2026-07-05T05:32:16.740055Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT07094685","Ivonescimab Before Surgery for the Treatment of Resectable Stage II-IV Head and Neck Cancer",[26],"2026-08-26T02:16:05.813655Z","2026-07-05T05:32:16.734917Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":51,"content_modified":52},"NCT06901531","A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer",[12],"2026-08-26T02:18:33.598205Z","2026-07-05T05:32:16.705484Z",{"nct_id":54,"title":55,"phases":56,"status":13,"updated_at":57,"content_modified":58},"NCT06899126","Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer",[12],"2026-08-26T02:18:58.141497Z","2026-07-05T05:32:16.701037Z",{"nct_id":60,"title":61,"phases":62,"status":13,"updated_at":63,"content_modified":64},"NCT07388524","Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial",[12],"2026-08-26T02:17:57.997171Z","2026-07-05T03:45:20.251331Z",{"nct_id":66,"title":67,"phases":68,"status":13,"updated_at":70,"content_modified":71},"NCT03424005","A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer",[69],"Phase 1\u002FPhase 2","2026-08-26T02:15:26.669629Z","2026-06-17T19:21:16.689089Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT04302025","A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)",[26],"2026-08-26T02:16:08.402952Z","2026-06-16T05:54:07.906610Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":83,"content_modified":84},"NCT04613596","Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7",[82],"Phase 2\u002FPhase 3","2026-08-26T02:16:20.336282Z","2026-06-16T05:54:07.905720Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT07554339","A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015\u002FKANDLELIT-015)",[12],"2026-08-26T02:15:44.309045Z","2026-06-04T01:30:07.902092Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT05420948","A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer",[26],"2026-08-26T02:15:15.642947Z","2026-05-13T02:55:06.348673Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06275360","Repositioning Immunotherapy in VetArans With Lung Cancer",[26],"2026-08-26T02:18:03.638950Z","2026-05-05T02:43:29.714483Z",{"nct_id":104,"title":105,"phases":106,"status":13,"updated_at":101,"content_modified":107},"NCT07361510","A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)",[12],"2026-05-05T02:43:29.714186Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT06772623","Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations",[69],"2026-08-26T02:15:30.699880Z","2026-05-05T02:43:29.702001Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":118,"content_modified":119},"NCT06793215","A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer",[12],"2026-08-26T02:18:45.196599Z","2026-05-05T02:43:29.700315Z",{"nct_id":121,"title":122,"phases":123,"status":13,"updated_at":124,"content_modified":125},"NCT05211895","A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC",[12],"2026-08-26T02:17:51.502023Z","2026-05-05T02:43:29.494562Z",{"nct_id":127,"title":128,"phases":129,"status":13,"updated_at":130,"content_modified":131},"NCT06731413","Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w\u002FAdv \u003C50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)",[26],"2026-08-26T02:15:02.712396Z","2026-05-05T02:43:29.397073Z",{"nct_id":133,"title":134,"phases":135,"status":13,"updated_at":136,"content_modified":137},"NCT06357533","Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations",[12],"2026-08-26T02:18:51.833592Z","2026-05-05T02:43:29.334773Z",{"nct_id":139,"title":140,"phases":141,"status":13,"updated_at":142,"content_modified":143},"NCT05491226","Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation",[26],"2026-08-26T02:17:04.346841Z","2026-05-05T02:43:29.329083Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT06764875","A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer",[12],"2026-08-26T02:18:59.761994Z","2026-05-05T02:43:29.164625Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":154,"content_modified":155},"NCT07227298","Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers",[69],"2026-08-26T02:17:44.240289Z","2026-05-05T02:43:29.138008Z",{"nct_id":157,"title":158,"phases":159,"status":13,"updated_at":160,"content_modified":161},"NCT06769698","A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",[26],"2026-08-26T02:19:30.857183Z","2026-05-05T02:43:29.044914Z",{"nct_id":163,"title":164,"phases":165,"status":13,"updated_at":166,"content_modified":167},"NCT04267848","Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])",[12],"2026-08-26T02:16:58.658552Z","2026-05-05T02:43:29.023848Z",{"nct_id":169,"title":170,"phases":171,"status":13,"updated_at":173,"content_modified":174},"NCT06912087","Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC",[172],"Phase 1","2026-08-26T02:18:53.782384Z","2026-05-05T02:43:29.015140Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT06875310","A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)",[12],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:28.985727Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT06096844","Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial",[12],"2026-08-26T02:16:40.941792Z","2026-05-05T02:43:28.875091Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT04796012","VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed\u002FRefractory Solid Tumors",[69],"2026-08-26T02:16:51.982021Z","2026-05-05T02:43:28.853446Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":197,"content_modified":198},"NCT05669846","Study of Healthy Donor FMT (hdFMT) and Pembrolizumab in Relapsed\u002FRefractory (R\u002FR) PD-L1 Positive NSCLC",[26],"2026-08-26T02:19:15.498463Z","2026-05-05T02:43:28.839540Z",{"nct_id":200,"title":201,"phases":202,"status":13,"updated_at":203,"content_modified":204},"NCT06758401","This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.",[12],"2026-08-26T02:18:17.007929Z","2026-05-05T02:43:28.792949Z",{"nct_id":206,"title":207,"phases":208,"status":13,"updated_at":209,"content_modified":210},"NCT07213934","Phase I\u002F II Trial Combining PD-1 Inhibition and Neoadjuvant Proton or Photon Radiation Therapy in Recurrent Head and Neck Squamous Cell Carcinoma",[69],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:28.733927Z",{"nct_id":212,"title":213,"phases":214,"status":13,"updated_at":215,"content_modified":216},"NCT06623656","Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC",[26],"2026-08-26T02:16:16.995720Z","2026-05-05T02:43:28.709931Z",{"nct_id":218,"title":219,"phases":220,"status":13,"updated_at":221,"content_modified":222},"NCT05715229","Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy",[26],"2026-08-26T02:16:03.788292Z","2026-05-05T02:43:28.654619Z",{"nct_id":224,"title":225,"phases":226,"status":13,"updated_at":227,"content_modified":228},"NCT06345729","A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004\u002FKANDLELIT-004)",[12],"2026-08-26T02:15:09.079045Z","2026-05-05T02:43:28.402965Z",{"nct_id":230,"title":231,"phases":232,"status":13,"updated_at":233,"content_modified":234},"NCT07173751","ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer",[12],"2026-08-26T02:18:01.700186Z","2026-05-05T02:43:28.399585Z",{"nct_id":236,"title":237,"phases":238,"status":13,"updated_at":239,"content_modified":240},"NCT05570825","SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer",[26],"2026-08-26T02:17:07.954622Z","2026-05-05T02:43:28.334370Z",{"nct_id":242,"title":243,"phases":244,"status":13,"updated_at":245,"content_modified":246},"NCT05799144","pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w\u002FAdvanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer",[26],"2026-08-26T02:16:10.529598Z","2026-05-05T02:43:28.217841Z",{"nct_id":248,"title":249,"phases":250,"status":13,"updated_at":251,"content_modified":252},"NCT05501665","Split Course Adaptive Radiation Therapy With Pembrolizumab With\u002FWithout Chemotherapy for Treating Stage IV Lung Cancer",[69],"2026-08-26T02:16:28.221034Z","2026-05-05T02:43:28.214093Z",{"nct_id":254,"title":255,"phases":256,"status":13,"updated_at":257,"content_modified":258},"NCT06788990","FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC",[82],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:28.180688Z",{"nct_id":260,"title":261,"phases":262,"status":13,"updated_at":263,"content_modified":264},"NCT06636734","Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP Trial",[26],"2026-08-26T02:16:24.970704Z","2026-05-05T02:43:28.112845Z",{"nct_id":266,"title":267,"phases":268,"status":13,"updated_at":269,"content_modified":270},"NCT07222566","Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer",[12],"2026-08-26T02:18:54.586325Z","2026-05-05T02:43:28.011803Z",{"nct_id":272,"title":273,"phases":274,"status":13,"updated_at":124,"content_modified":275},"NCT04534205","A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1",[82],"2026-05-05T02:43:28.001380Z",{"nct_id":277,"title":278,"phases":279,"status":13,"updated_at":112,"content_modified":280},"NCT06525220","A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)",[12],"2026-05-05T02:43:27.989461Z",{"nct_id":282,"title":283,"phases":284,"status":13,"updated_at":286,"content_modified":287},"NCT07059494","Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant",[285],"Phase 4","2026-08-26T02:17:32.059863Z","2026-05-05T02:43:27.947322Z",{"nct_id":289,"title":290,"phases":291,"status":13,"updated_at":292,"content_modified":293},"NCT06234397","Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors",[172],"2026-08-26T02:17:12.307088Z","2026-05-05T02:43:27.845053Z",{"nct_id":295,"title":296,"phases":297,"status":13,"updated_at":298,"content_modified":299},"NCT06103864","A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer",[12],"2026-08-26T02:18:14.396999Z","2026-05-05T02:43:27.810861Z",{"nct_id":301,"title":302,"phases":303,"status":13,"updated_at":304,"content_modified":305},"NCT06498635","Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial",[12],"2026-08-26T02:19:18.331180Z","2026-05-05T02:43:27.808821Z",{"nct_id":307,"title":308,"phases":309,"status":13,"updated_at":45,"content_modified":310},"NCT07465276","Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC",[26],"2026-05-05T02:43:27.642456Z"]